IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera.
BACKGROUND
Chronic urticaria is thought to be an autoimmune disorder in 35-40% of patients because of the presence of an immunoglobulin G (IgG) antibody reactive with the IgE receptor. Patients possessing this antibody are identified by the ability of serum to degranulate donor basophils to release histamine. We questioned whether priming of basophils with interleukin 3 (IL3) would facilitate identification of patients and/or alter the percentage of patients who have a positive assay.


METHODS
We incubated 37 chronic urticaria sera with basophils from donors with no urticaria with and without priming with IL3 and compared histamine release in each instance. We also preincubated basophils from a 'non-releaser' with IL3, used these cells to assay chronic urticaria sera, and assessed the contribution of complement.


RESULTS
Interleukin 3 increases the amount of histamine release by the sera which is able to activate basophils, but it does not convert negative sera into positive releasers. Interleukin 3 is able to partially reverse 'non-releaser' basophils into cells that respond to chronic urticaria sera, and complement cannot account for the augmentation seen.


CONCLUSIONS
Preincubating basophils with IL3 facilitates the identification of sera with anti-IgE receptor antibody but does not affect the percentage of sera designated as positive.
Ferrer
M
M
Department of Allergy and Clinical Immunology, Clinica Universitaria, Universidad de Navarra, Pamplona, Spain.
Luquin
E
E
Kaplan
A P
AP
D000328:Adult; D001491:Basophils / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007377:Interleukin-3 / Q000494:pharmacology*; D008297:Male; D014581:Urticaria / Q000097:blood*
D007377:Interleukin-3